Home・Listă Acțiuni・Xencor Inc

Xencor Inc

Închisă

SectorSănătate

19.36 -0.62

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

18.87

Maxim

19.85

Indicatori cheie
By Trading Economics
Venit	-214M -129M
Vânzări	-24M 4.5M
EPS	-1.71
Marjă de profit	-2,854.65
Angajați	260
EBITDA	-127M -121M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+23.4% upside

Dividende
By Acuity
Următoarele câștiguri	4 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	404M 1.4B
Deschiderea anterioară	19.98
Închiderea anterioară	19.36

Sentimentul știrilor

By Acuity

50%

163 / 340 Clasament în Healthcare

Xencor Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 iul. 2026, 19:11 UTC

Xencor Inc shares are lower in Friday's session, reflecting broader market trends. No specific news was identified to explain the price movement.

22 iul. 2026, 20:06 UTC

Xencor Inc shares are lower today, retracing from an earlier peak. Broader market sentiment is affected by uncertainty ahead of the Federal Reserve meeting.

21 iul. 2026, 19:02 UTC

Social Media

Xencor Inc. shares reached a new 52-week high, driven by developments in RCC related to ENPP3 and immuno-oncology efforts involving TL1A.

20 iul. 2026, 19:41 UTC

Social Media

Xencor Inc's shares are higher as clinical results are accepted for presentation at the ESMO conference, with a Phase 3 trial planned for 2027.

Comparație

Modificare preț

Xencor Inc Așteptări

Obiectiv de preț

By TipRanks

23.4% sus

Prognoză pe 12 luni

Medie 24.1 USD 23.4%

Maxim 38 USD

Minim 13 USD

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruXencor Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

11 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 11 analiști care au acordat evaluări ale acțiunilor Xencor Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

163 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.